Welldoc announced today that it received the 10th FDA 510(k) clearance for its BlueStar diabetes digital health solution.
The latest regulatory nod enables BlueStar to use connected insulin dosing data in personalized bolus insulin dosing recommendations. Columbia, Maryland-based Welldoc aims to make this enhanced functionality available commercially in 2024.
Get the full story at our sister site, Drug Delivery Business News.